BIOLIFE SOLUTIONS INC
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During our fiscal quarter ended March 31, 2024, certain of our officers (as defined in Rule 16a-1(f) under the Exchange Act) and directors entered into contracts, instructions, or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Securities and Exchange Act of 1934, as amended (“Rule 10b5-1(c)”), for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We refer to these contracts, instructions, and written plans as “Rule 10b5-1 trading plans” and each one as a “Rule 10b5-1 trading plan.”The following table identifies and provides the material terms of the Rule 10b5-1 trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)adopted orterminated by our officers and directors during the three months ended March 31, 2024.
| Name and Position | Plan Adoption / Termination | Plan Adoption / Termination Date | Expiration Date | Number of Shares to be Purchased (Sold) under Plan |
|---|---|---|---|---|
| Aby J. Mathew, EVP & Chief Scientific Officer | Adoption | March 13, 2024 | December 31, 2024 | (123,404) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.